Drug Development · global
New Phase 3 olorofim data: fewer renal adverse events, but liver injury risk still warrants attention
Following the June announcement that the primary endpoint was met, the OASIS trial has disclosed longer-term mortality and organ safety results, clarifying the benefits and limitations of this new oral antifungal candidate.
For immunocompromised patients with invasive aspergillosis, controlling infection and tolerating drug toxicity are often simultaneous challenges. On October 21, F2G and Shionogi announced further results from the Phase 3 OASIS trial of the oral candidate olorofim: compared with a strategy starting with AmBisome followed by standard treatment, drug-related renal adverse events were less frequent, but liver injury remains a safety signal requiring attention.
This disclosure builds on the primary endpoint results announced in June, adding Day 84 mortality and more detailed safety data, with presentation scheduled for October 22 at IDWeek 2026. Independent reporting by Chemical & Engineering News also distinguished the June topline announcement from these expanded results; the significance of the new data lies in the emerging clinical picture beyond the earlier finding that noninferiority was met.
OASIS randomized 225 adults to the olorofim or control group, with 151 and 74 patients, respectively. Azole antifungal treatment had failed in these patients or was unsuitable because of factors including resistance, intolerance, and drug interactions. Day 42 all-cause mortality was 23.8% and 24.3%, respectively, a difference of −0.5 percentage points; the 95% confidence interval ranged from −13.1 to 10.8 percentage points, meeting the prespecified noninferiority margin of 20 percentage points. This supports the trial's specified noninferiority conclusion and does not demonstrate that olorofim reduces mortality.
The longer follow-up also needs to be considered. Day 84 mortality was 32.5% in the olorofim group and 29.7% in the control group, and the 95% confidence interval for the difference still crossed zero, preventing a determination of which group had a survival advantage. Oral administration provides another route of treatment, but cannot be directly equated with better long-term efficacy.
Regarding safety, renal adverse events judged by investigators to be drug-related occurred in 1.3% and 22.2% of the two groups, respectively; the safety analysis included 151 patients in the olorofim group and 72 in the control group. However, drug-induced liver injury judged through expert review to be at least possibly related to treatment occurred in 4.6% and 4.2%, respectively. The finding of fewer renal events cannot be extended to mean there is no risk of organ toxicity.
### Background
Invasive aspergillosis primarily threatens immunocompromised people, and alternatives become more limited when commonly used azole drugs fail or are difficult to use. Olorofim inhibits fungal dihydroorotate dehydrogenase (DHODH), disrupting the synthesis of pyrimidines needed to make DNA and RNA. Its mechanism of action differs from those of several existing classes of antifungal drugs; one of its development goals is to address treatment gaps, including those involving azole-resistant strains.
F2G expects to resubmit its marketing application to the U.S. Food and Drug Administration by the end of 2026. However, olorofim remains investigational, these data come primarily from a company announcement, and the conference presentation has yet to take place. Regulatory review will still require a comprehensive assessment of efficacy, safety, and trial design, and these results in patients for whom azole treatment was unsuitable or had failed cannot be directly generalized to all patients with invasive aspergillosis.